PL2935330T3 - Przeciwciała przeciw notch3 - Google Patents
Przeciwciała przeciw notch3Info
- Publication number
- PL2935330T3 PL2935330T3 PL13818154T PL13818154T PL2935330T3 PL 2935330 T3 PL2935330 T3 PL 2935330T3 PL 13818154 T PL13818154 T PL 13818154T PL 13818154 T PL13818154 T PL 13818154T PL 2935330 T3 PL2935330 T3 PL 2935330T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies against
- against notch3
- notch3
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739435P | 2012-12-19 | 2012-12-19 | |
| US201361866787P | 2013-08-16 | 2013-08-16 | |
| EP13818154.0A EP2935330B1 (en) | 2012-12-19 | 2013-12-19 | Anti-notch3 antibodies |
| PCT/US2013/076615 WO2014100435A1 (en) | 2012-12-19 | 2013-12-19 | Anti-notch3 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2935330T3 true PL2935330T3 (pl) | 2019-11-29 |
Family
ID=49918920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13818154T PL2935330T3 (pl) | 2012-12-19 | 2013-12-19 | Przeciwciała przeciw notch3 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9879083B2 (pl) |
| EP (1) | EP2935330B1 (pl) |
| DK (1) | DK2935330T3 (pl) |
| ES (1) | ES2737649T3 (pl) |
| PL (1) | PL2935330T3 (pl) |
| WO (1) | WO2014100435A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2935330T3 (pl) | 2012-12-19 | 2019-11-29 | Aveo Pharmaceuticals Inc | Przeciwciała przeciw notch3 |
| WO2014159239A2 (en) * | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
| WO2016046053A1 (en) * | 2014-09-25 | 2016-03-31 | H. Lundbeck A/S | Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy |
| KR20180054639A (ko) * | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| DK3448420T3 (da) * | 2016-04-29 | 2022-12-12 | Aveo Pharmaceuticals Inc | Anti-notch3-antistof |
| US11453718B2 (en) | 2017-03-27 | 2022-09-27 | The Schepens Eye Research Institute, Inc. | NOTCH3 agonist compositions and methods for treating small vessel diseases |
| US20200103419A1 (en) | 2017-03-27 | 2020-04-02 | The Schepens Eye Research Institute, Inc. | Blood biomarkers and diagnostic methods for small vessel diseases |
| EP3801767A1 (en) | 2018-06-08 | 2021-04-14 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| CA2491864C (en) | 2001-07-12 | 2012-09-11 | Jefferson Foote | Super humanized antibodies |
| PE20081264A1 (es) * | 2006-10-19 | 2008-10-01 | Genentech Inc | Anticuerpos agonistas anti-notch3 |
| CL2007003661A1 (es) * | 2006-12-18 | 2008-07-18 | Genentech Inc | Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3. |
| AU2008209482B2 (en) * | 2007-01-24 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| ES2531541T3 (es) * | 2008-07-08 | 2015-03-17 | Oncomed Pharmaceuticals, Inc. | Agentes de unión del receptor Notch1 y procedimientos de uso de los mismos |
| US7544476B1 (en) | 2008-07-11 | 2009-06-09 | Aveo Pharmaceuticals, Inc. | Identifying cancers sensitive to treatment with inhibitors of notch signaling |
| MA33973B1 (fr) * | 2009-09-30 | 2013-02-01 | Genentech Inc | Méthodes de traitement du cancer à l'aide d'antagonistes de notch |
| WO2012003472A1 (en) | 2010-07-02 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
| BR112015010436A2 (pt) * | 2012-11-07 | 2017-08-22 | Pfizer | Anticorpos anti-notch3 e conjugados anticorpo-fármaco |
| PL2935330T3 (pl) * | 2012-12-19 | 2019-11-29 | Aveo Pharmaceuticals Inc | Przeciwciała przeciw notch3 |
-
2013
- 2013-12-19 PL PL13818154T patent/PL2935330T3/pl unknown
- 2013-12-19 US US14/653,684 patent/US9879083B2/en active Active
- 2013-12-19 EP EP13818154.0A patent/EP2935330B1/en active Active
- 2013-12-19 DK DK13818154.0T patent/DK2935330T3/da active
- 2013-12-19 WO PCT/US2013/076615 patent/WO2014100435A1/en not_active Ceased
- 2013-12-19 ES ES13818154T patent/ES2737649T3/es active Active
-
2018
- 2018-01-08 US US15/864,710 patent/US10745476B2/en active Active
-
2020
- 2020-08-13 US US16/992,897 patent/US12269877B2/en active Active
-
2025
- 2025-02-26 US US19/063,993 patent/US20250289884A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160185852A1 (en) | 2016-06-30 |
| DK2935330T3 (da) | 2019-07-22 |
| US20180230213A1 (en) | 2018-08-16 |
| EP2935330B1 (en) | 2019-04-24 |
| US9879083B2 (en) | 2018-01-30 |
| ES2737649T3 (es) | 2020-01-15 |
| US10745476B2 (en) | 2020-08-18 |
| WO2014100435A1 (en) | 2014-06-26 |
| US12269877B2 (en) | 2025-04-08 |
| EP2935330A1 (en) | 2015-10-28 |
| US20210171627A1 (en) | 2021-06-10 |
| US20250289884A1 (en) | 2025-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024011I1 (el) | Αντισωματα anti-fcrn | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| HRP20181646T1 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| PT2878018T (pt) | Resumo | |
| PT2819623T (pt) | Resumo | |
| EP2763896A4 (en) | UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS | |
| DK3117837T3 (da) | Antistofformuleringer | |
| DK2859055T3 (da) | Polymercoatings | |
| DK2825087T3 (da) | Otoscanner | |
| EP2809145A4 (en) | CHLOROPLAST TRANSIT PEPTIDES | |
| DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
| EP2814472A4 (en) | DITHIOAMINE REDUCING AGENTS | |
| EP2824794A4 (en) | Charging cable | |
| EP2805877A4 (en) | UNDER HOOD | |
| DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
| DE112012006109A5 (de) | Okklusionsschienenanordnung | |
| BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
| DK2854722T3 (da) | Stomipose | |
| PT2674413T (pt) | Resumo | |
| PT2831109T (pt) | Resumo | |
| PT2825212T (pt) | Resumo | |
| EP2831482A4 (en) | Flange gasket | |
| EP2816694A4 (en) | FLAT CABLE WINDING DEVICE | |
| DK2825157T3 (da) | Aminosyrelipider | |
| EP2809729A4 (en) | Siloxane polyether copolymers |